Role of Metabolic Surgery in Less Obese or Non-Obese Subjects with Type 2 Diabetes: Influence Over Cardiovascular Events

  • Ricardo Cohen
  • Pedro Paulo Caravatto
  • Tarissa Petry
  • David Cummings
Lipid and Metabolic Effects of Gastrointestinal Surgery (FR Rubino, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Lipid and Metabolic Effects of Gastrointestinal Surgery

Abstract

Bariatric surgery was initially developed as a tool for weight reduction only, but it is gaining increasing popularity because of its remarkable effect on glucose metabolism in morbidly obese and less obese patients. Recent publications have shown the good results of metabolic surgery, creating a new field of clinical research that is currently overflowing in the medical community with outstanding high-quality data. In morbidly obese population, there is compelling data on long term cardiovascular risk reduction and mortality, coming from longitudinal prospective studies and systematic reviews. Numbers range from 33 to 92 % of decrease in fatal and nonfatal cardiovascular events . In low body mass index (BMI) diabetics, there is an increasing number of reported good outcomes after metabolic surgery with the aim to treat type 2 diabetes (T2DM). There is scarce information on cardiovascular outcomes in non–morbidly obese subjects, but the extraordinary glucose, lipid and blood pressure control in the published series are suggesting good long-term effects on cardiovascular risk profile and mortality. The papers review was comprehensive, including the available randomized controlled trials, long-term prospective series and systematic reviews.

Keywords

Type 2 diabetes mellitus Metabolic surgery Bariatric surgery Obesity Gastrointestinal surgery 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    American Diabetes Association. Economic costs of diabetes in the U.S. in 2012. Diabetes Care. 2013;36:1033–46.CrossRefGoogle Scholar
  2. 2.
    Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8:29.PubMedCrossRefGoogle Scholar
  3. 3.
    Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011;94:311–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. NEJM. 2003;348:383–93.PubMedCrossRefGoogle Scholar
  5. 5.
    Murray P, Chune GW, Raghavan VA. Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials. Curr Atheroscler Rep. 2010;12:432–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. New Engl J Med. 2008;358:580–91.PubMedCrossRefGoogle Scholar
  7. 7.
    American Diabetes Association. Standards of medical care in diabetes 2011. Diabetes Care. 2011;34:S11–61.CrossRefGoogle Scholar
  8. 8.
    • Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988–2010. Diabetes Care. 2013;(in press). doi:10.2337/dc12-2258. Recent report on the “3 endpoints” results achieved in T2DM treatment.
  9. 9.
    Grant RW, Buse JB, Meigs JB, University Health System Consortium (UHC) Diabetes Benchmarking Project Team. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diabetes Care. 2005;28:337–442.PubMedCrossRefGoogle Scholar
  10. 10.
    Cohen R, Caravatto PP, Petry T. Surgery for Diabetes. Curr Surg Rep. 2013;(in press). doi:10.1007/s40137-013-0023-0.
  11. 11.
    Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–604.PubMedCrossRefGoogle Scholar
  12. 12.
    • Cohen R, Caravatto PP, Petry Z. Metabolic surgery for type 2 diabetes in patients with a BMI of <35 kg/m2: a Surgeon’s perspective. Obes Surg. 2013;23:809–18. A comprehensive review of metabolic surgery in BMIs below 35 kg/m 2.PubMedCrossRefGoogle Scholar
  13. 13.
    Shah SS, Todkar JS, Shah PS, et al. Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index. Surg Obes Relat Dis. 2010;6:332–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Cohen RV, Rubino F, Schiavon C, et al. Diabetes remission without weight loss after duodenal bypass surgery. Surg Obes Relat Dis. 2011;8:66–8.CrossRefGoogle Scholar
  15. 15.
    Cohen RV, Schiavon CA, Pinheiro Filho JC, et al. Laparoscopic bariatric surgery: new technologies, trends and perspectives. Rev Hosp Clin Fac Med Sao Paulo. 2003;58:I–VIII.PubMedCrossRefGoogle Scholar
  16. 16.
    Geloneze B, Geloneze SR, Chaim E, et al. Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study. Ann Surg. 2012;256:72–8.PubMedCrossRefGoogle Scholar
  17. 17.
    DePaula AL, Macedo ALV, Rassi N, et al. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc. 2007;22:706–16.CrossRefGoogle Scholar
  18. 18.
    Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care. 2008;31:S290–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Cummings DE, Flum DR. Gastrointestinal surgery as a treatment for diabetes. JAMA. 2008;299:341–3.PubMedCrossRefGoogle Scholar
  20. 20.
    Yamaoka K, Tango T. Efficacy of lifestyle education to prevent type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetes Care. 2005;28:2780–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Li Q, Chen L, Yang Z, et al. Metabolic effects of bariatric surgery in type 2 diabetic patients with body mass index. Diabetes Obes Metab. 2011;14:262–70.PubMedCrossRefGoogle Scholar
  22. 22.
    •• Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307:56–65. Landmark paper that analyses cardiovascular outcomes after 20 years follow up. Shows that the ony CV predicting factor was fasting insuli and not BMI.PubMedCrossRefGoogle Scholar
  23. 23.
    Bianchi C, Del Prato S. Metabolic memory and individual treatment aims in type 2 diabetes outcome – lessons learned from large clinical trials. Rev Diabet Stud. 2011;8:432–40.PubMedCrossRefGoogle Scholar
  24. 24.
    Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk for complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.Google Scholar
  25. 25.
    Look AHEAD Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD Trial. Arch Intern Med. 2010;170:1566–75.CrossRefGoogle Scholar
  26. 26.
    Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308:2489–96.PubMedCrossRefGoogle Scholar
  27. 27.
    • Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2012;23:93–102. Interesting paper that analyses the long term effects of bariatric surgery & T2DM.CrossRefGoogle Scholar
  28. 28.
    Arterburn DE, O’Connnor PJ. A look ahead at the future of diabetes prevention and treatment. JAMA. 2012;308:2517–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Rubino F. Bariatric surgery: effects on glucose homeostasis. Curr Opin Clin Nutr Metab Care. 2006;9:497–507.PubMedCrossRefGoogle Scholar
  30. 30.
    Rubino F, Marescaux J. Effect of duodenal–jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg. 2004;239:1–11.PubMedCrossRefGoogle Scholar
  31. 31.
    Cohen RV, Schiavon CA, Pinheiro JS, et al. Duodenal-jejunal bypass for the treatment of type 2 diabetes in patients with body mass index of 22–34 kg/m2: a report of 2 cases. Surg Obes Relat Dis. 2007;3:195–7.PubMedCrossRefGoogle Scholar
  32. 32.
    Cohen R, Caravatto PP, Correa JL, et al. Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis. 2012;8:375–80.PubMedCrossRefGoogle Scholar
  33. 33.
    Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85.PubMedCrossRefGoogle Scholar
  34. 34.
    • Cohen R, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35:1420–8. Longest follow up of bariatric surgery in BMIs < 35.PubMedCrossRefGoogle Scholar
  35. 35.
    Kim S, Richards WO. Long-term follow-up of the metabolic profiles in obese patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass. Ann Surg. 2010;251:1049–55.PubMedCrossRefGoogle Scholar
  36. 36.
    Asztalos BF, Swarbrick MM, Schaefer EJ, et al. Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women. J Lipid Res. 2010;51:2405–12.PubMedGoogle Scholar
  37. 37.
    Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380:572–80.PubMedCrossRefGoogle Scholar
  38. 38.
    Prati P, Vanuzzo D, Casaroli M, et al. Prevalence and determinants of carotid atherosclerosis in a general population. Stroke. 1992;23:1705–11.PubMedCrossRefGoogle Scholar
  39. 39.
    Adams TD, Gress RE, Smith SC, et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007;357:753–61.PubMedCrossRefGoogle Scholar
  40. 40.
    Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012;367:695–704.PubMedCrossRefGoogle Scholar
  41. 41.
    Romeo S, Maglio C, Burza MA, et al. Cardiovascular events after bariatric surgery in obese subjects with type 2 diabetes. Diabetes Care. 2012;35:2613–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Heneghan HM, Meron-Eldar S, Brethauer SA, Schauer PR, Young JB. Effect of bariatric surgery on cardiovascular risk profile. AJC. 2011;108(10):1499–507.CrossRefGoogle Scholar
  43. 43.
    Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98(24):1763–1777.Google Scholar
  44. 44.
    •• Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery vs. intensive medical therapy in obese patients with diabetes. New Engl J Med. 2012;366:1567–76.PubMedCrossRefGoogle Scholar
  45. 45.
    •• Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. New Engl J Med. 2012;366:1577–85. First 2 RCTs that compared surgery versus medical treatment focusing T2DM.PubMedCrossRefGoogle Scholar
  46. 46.
    Maggard-Gibbons M, Maglione M, Livhits M, Ewing B, Maher AR, Hu J, et al. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA. 2013;309(21):2250–61.PubMedCrossRefGoogle Scholar
  47. 47.
    Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes. A randomized controlled trial. JAMA. 2008;299:316–23.PubMedCrossRefGoogle Scholar
  48. 48.
    Sultan S, Parikh M, Youn H, Kurian M, Fielding G, Ren C. Early U.S. outcomes after laparoscopic adjustable gastric banding in patients with a body mass index less than 35 kg/m2. Surg Endosc. 2009;23:1569–73.PubMedCrossRefGoogle Scholar
  49. 49.
    Lee WJ, Ser KH, Chong K, et al. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Surgery. 2010;147:664–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Lee WJ, Hur KY, Lakadawala M, et al. Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study. J Gastrointest Surg. 2012;16:45–52.PubMedCrossRefGoogle Scholar
  51. 51.
    Abbatini F, Capoccia D, Casella G, et al. Type 2 diabetes in obese patients with body mass index of 30–35 kg/m2: sleeve gastrectomy versus medical treatment. Surg Obes Relat Dis. 2012;8:20–4.PubMedCrossRefGoogle Scholar
  52. 52.
    Lee WJ, Chong K, Chen CY, et al. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index < 35kg/m2. Obes Surg. 2011;21:889–95.PubMedCrossRefGoogle Scholar
  53. 53.
    Scopinaro N, Adami GF, Papadis FS, et al. Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg. 2011;253:699–703.PubMedCrossRefGoogle Scholar
  54. 54.
    Chellini C, Rubino F, Castagneto M, et al. The effect of bilio-pancreatic diversion on type 2 diabetes in patients with BMI < 35 kg/m2. Diabetologia. 2009;52:1027–30.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Ricardo Cohen
    • 1
  • Pedro Paulo Caravatto
    • 1
  • Tarissa Petry
    • 1
  • David Cummings
    • 2
  1. 1.The Center of Excellence of Metabolic and Bariatric SurgeryOswaldo Cruz HospitalSão PauloBrazil
  2. 2.Diabetes and Obesity Center of Excellence and Veterans Affairs Puget Sound Health Care SystemUniversity of Washington School of MedicineSeattleUSA

Personalised recommendations